Protein:GRIA2 |
Protein Summary |
 Gene summary |
| Gene name: GRIA2 | ASpdb.0 ID: 2891 | Gene | Gene symbol | GRIA2 | Gene ID | 2891 |
| Gene name | glutamate ionotropic receptor AMPA type subunit 2 |
| Synonyms | GLUR2|GLURB|GluA2|GluR-K2|HBGR2|NEDLIB|gluR-2|gluR-B |
| Cytomap | 4q32.1 |
| Type of gene | protein-coding |
| Description | glutamate receptor 2AMPA receptor subunit GluA2AMPA-selective glutamate receptor 2glutamate receptor, ionotropic, AMPA 2 |
| Modification date | 20240403 |
| UniProtAcc | P42262 |
| Gene ontology of this gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Gene | GRIA2 | GO:0004970 | glutamate-gated receptor activity | 20614889 |
| Gene | GRIA2 | GO:0035235 | ionotropic glutamate receptor signaling pathway | 20614889 |
AS Summary |
| Information of the canonical protein with experimentally identified structure from PDB (2023). |
| UniProt Acc | File name | PDB ID | Method | Resolution | Chain | Start | End |
| P42262-1 | P42262-1_2wjw_A.pdb | 2WJW | X-ray | 1.8 | A | 25 | 398 |
| ASpdb's canonical and alternatively spliced isoform information. |
| accession_id | gene_name | canonical_id | alternative_id | canonical_length | alternative_length | canonical_start | canonical_end | type | originalSEQ | variationSEQ | alternative_start | alternative_end |
| P42262 | GRIA2 | P42262-1 | P42262-2 | 883 | 883 | 765 | 800 | Substitution | NAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGD | TPVNLAVLKLSEQGVLDKLKNKWWYDKGECGAKDSG | 765 | 800 |
| P42262 | GRIA2 | P42262-1 | P42262-3 | 883 | 901 | 848 | 883 | Substitution | VAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI | MTLNDAMRNKARLSITGSTGENGRVMTPEFPKAVHAVPYVSPGMGMNVSVTDLS | 848 | 901 |
| P42262 | GRIA2 | P42262-1 | P42262-4 | 883 | 836 | 1 | 47 | Deletion | none | none | 0 | 0 |
| P42262 | GRIA2 | P42262-1 | P42262-4 | 883 | 836 | 765 | 800 | Substitution | NAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGD | TPVNLAVLKLSEQGVLDKLKNKWWYDKGECGAKDSG | 718 | 753 |
| Multiple sequence alignment of our canonical and alternatively spliced GRIA2 |
| Matched gene isoform IDs with Ensembl and RefSeq of our canonical and alternative spliced genes of GRIA2 |
| UniProt-id | ENSG | ENST | ENSP |
| P42262-1 | ENSG00000120251.22 | ENST00000264426.14 | ENSP00000264426.9 |
| P42262-2 | ENSG00000120251.22 | ENST00000296526.12 | ENSP00000296526.7 |
| P42262-3 | ENSG00000120251.22 | ENST00000645636.1 | ENSP00000495569.1 |
| P42262-4 | ENSG00000120251.22 | ENST00000393815.6 | ENSP00000377403.2 |
| P42262-4 | ENSG00000120251.22 | ENST00000507898.5 | ENSP00000426845.1 |
| P42262-4 | ENSG00000120251.22 | ENST00000703765.1 | ENSP00000515472.1 |
| UniProt-id | NM ID | NP ID |
| P42262-1 | NM_001083619.1 | NP_001077088.1 |
| P42262-2 | NM_000826.3 | NP_000817.2 |
| P42262-4 | NM_001083620.1 | NP_001077089.1 |
| Amino acid sequences of our canonical and alternatively spliced GRIA2 |
| accession_id | Protein sequence |
| P42262-1 | MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFG FYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINV GNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLV SKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNI KFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLA AEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLD PLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFT LIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGK YAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSL |
| P42262-2 | MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFG FYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINV GNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLV SKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNI KFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLA AEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLD PLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFT LIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGK YAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRTPVNLAVLKLSEQGVLDKLKNKWWYDKGECGAKDSGSKEKTSALSL |
| P42262-3 | MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFG FYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINV GNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLV SKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNI KFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLA AEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLD PLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFT LIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGK YAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSL SNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKMTLNDAMRNKARLSITGSTGENGRVMTPEFPKAVHAVPYVSPGMGMNVSVTDL |
| P42262-4 | MVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALL SLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIG KHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQ RIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGND TSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAI APLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSE STNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTK EFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRTPV NLAVLKLSEQGVLDKLKNKWWYDKGECGAKDSGSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINP |
Protein Functional Features |
| Main function of this protein. (from UniProt) |
| GRIA2 (go to UniProt):P42262 |
| Retention analysis result of protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Accession_id | Subsection | Start | End | Funcitonal feature | Splicing information |
| P42262 | Topological domain | 25 | 543 | Note=Extracellular;Ontology_term=ECO:0000250;evidence=ECO:0000250 | Type=Deletion;Start=1;End=47 |
| P42262 | Topological domain | 638 | 812 | Note=Extracellular;Ontology_term=ECO:0000250;evidence=ECO:0000250 | Type=Substitution;Start=765;End=800 |
| P42262 | Topological domain | 638 | 812 | Note=Extracellular;Ontology_term=ECO:0000250;evidence=ECO:0000250 | Type=Substitution;Start=765;End=800 |
| P42262 | Topological domain | 834 | 883 | Note=Cytoplasmic;Ontology_term=ECO:0000250;evidence=ECO:0000250 | Type=Substitution;Start=848;End=883 |
| P42262 | Region | 867 | 877 | Note=Required for interaction with IQSEC1;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P19491 | Type=Substitution;Start=848;End=883 |
Gene Isoform Structures and Expression Levels for GRIA2 |
| Gene structures of our canonical and alternative spliced genes of GRIA2 * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Expression levels of gene isoforms across GTEx. |
 |
| Expression levels of gene isoforms across TCGA. |
 |
Protein Structures |
| PDB and CIF files of the predicted protein structures * Here we show the 3D structure of the proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| 3D view using mol* of P42262-1 |
| 3D view using mol* of P42262-2 |
| 3D view using mol* of P42262-3 |
| 3D view using mol* of P42262-4 |
pLDDT Score Distribution |
| pLDDT score distribution of the predicted protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. |
| pLDDT distribution across the protein length of P42262-1 |
 |
| pLDDT distribution across the protein length of P42262-2 |
 |
| pLDDT distribution across the protein length of P42262-3 |
 |
| pLDDT distribution across the protein length of P42262-4 |
 |
Ramachandran Plot of Protein Structures |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this protein peptide. |
| Ramachandran plot of P42262-1 |
 |
| Ramachandran plot of P42262-3 |
 |
Potential Active Site Information |
| The potential binding sites of these proteins were identified using SiteMap, a module of the Schrodinger suite. |
| UniProt-id | Site score | Size | D score | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
| P42262-1 | 1.067 | 120 | 1.125 | 307.671 | 0.528 | 0.711 | 0.918 | 1.215 | 0.74 | 1.642 | 0.705 | 470,471,472,473,474,476,481,482,502,503,504,505,50 6,508,673,674,675,677,678,679,681,682,751 |
| P42262-2 | 1.117 | 83 | 0.831 | 141.316 | 0.284 | 0.97 | 1.296 | 0.157 | 1.864 | 0.084 | 0.418 | 423,426,471,499,500,501,506,670,671,674,675,676,70 6,707,708,723,724,725,726,729,753 |
| P42262-3 | 1.066 | 103 | 0.982 | 335.797 | 0.502 | 0.797 | 0.958 | 0.527 | 1.339 | 0.394 | 0.527 | 34,37,40,67,91,92,93,115,116,129,155,156,211,212,2 13,214,215,239,240,241,244,294,295,296 |
| P42262-4 | 1.061 | 125 | 1.098 | 317.275 | 0.47 | 0.744 | 0.971 | 1.19 | 0.883 | 1.347 | 0.574 | 423,424,425,426,427,428,429,432,434,435,456,457,45 8,459,625,626,627,628,630,631,632,634,635,704 |
Protein Structure and Feature Comparision |
| Protein Structure Comparision Using Template Modeling Scores (TM-score). |
 |
| Protein Structure Comparision Visualization with mol*. between Canonical predicted structure (AF2)(orange) vs Canonical validated structure (PDB)(green) |
| 3D view using mol* of P42262-1_P42262-1_2wjw_A.pdb |
| Protein Structure Comparision Visualization with mol*. between Canonical validated structure (PDB)(orange) vs Alternative predicted structure (AF2)(green) |
| 3D view using mol* of P42262-1_2wjw_A_P42262-2.pdb |
| 3D view using mol* of P42262-1_2wjw_A_P42262-3.pdb |
| 3D view using mol* of P42262-1_2wjw_A_P42262-4.pdb |
| Protein Structure Comparision Visualization with mol*. between Canonical predicted structure (AF2)(orange) vs Alternative predicted structure (AF2)(green) |
| 3D view using mol* of P42262-1_P42262-2.pdb |
| 3D view using mol* of P42262-1_P42262-3.pdb |
| 3D view using mol* of P42262-1_P42262-4.pdb |
| Protein Feature Comparison of the protein sequendary structures among the protiens. |
| ./stats/secondary_structure/figure/P42262-1_vs_P42262-2.png |
 < |
| ./stats/secondary_structure/figure/P42262-1_vs_P42262-3.png |
 < |
| ./stats/secondary_structure/figure/P42262-1_vs_P42262-4.png |
 < |
| Protein Feature Comparison of the relative accessible surface area (ASA) among the protiens. |
| ./stats/relative_asa/P42262-1_vs_P42262-2.png |
 < |
| ./stats/relative_asa/P42262-1_vs_P42262-3.png |
 < |
| ./stats/relative_asa/P42262-1_vs_P42262-4.png |
 < |
Protein-Protein Interaction |
| Interactors from UniProt. |
| Accession_id | Subsection | Start | End | Funcitonal feature | Splicing information |
| P42262 | Region | 867 | 877 | Note=Required for interaction with IQSEC1;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P19491 | Type=Substitution;Start=848;End=883 |
| Interactors from STRING. |
| Gene name | Interactors |
Related Drugs to GRIA2 |
| Drugs targeting this gene/protein. (DrugBank) |
| UniProt accession | Gene name | DrugBank ID | Drug name | Drug group | Actions |
| P42262 | GRIA2 | DB08304 | (3R)-3-cyclopentyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide | experimental | |
| P42262 | GRIA2 | DB08303 | (3S)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide | experimental | |
| P42262 | GRIA2 | DB04599 | Aniracetam | experimental | |
| P42262 | GRIA2 | DB02999 | Quisqualic acid | experimental | |
| P42262 | GRIA2 | DB01346 | Quinidine barbiturate | approved | antagonist |
| P42262 | GRIA2 | DB04798 | THIO-ATPA | experimental | |
| P42262 | GRIA2 | DB00418 | Secobarbital | approved, vet_approved | antagonist |
| P42262 | GRIA2 | DB04982 | Talampanel | investigational | |
| P42262 | GRIA2 | DB02347 | 2-Amino-3-(5-Tert-Butyl-3-(Phosphonomethoxy)-4-Isoxazolyl)Propionic Acid | experimental | |
| P42262 | GRIA2 | DB00849 | Methylphenobarbital | approved | antagonist |
| P42262 | GRIA2 | DB05047 | CX-717 | illicit, investigational | |
| P42262 | GRIA2 | DB02057 | (S)-AMPA | experimental | |
| P42262 | GRIA2 | DB13146 | Fluciclovine (18F) | approved | inhibitor |
| P42262 | GRIA2 | DB00312 | Pentobarbital | approved, investigational, vet_approved | antagonist |
| P42262 | GRIA2 | DB00306 | Talbutal | approved, illicit | antagonist |
| P42262 | GRIA2 | DB00142 | Glutamic acid | approved, nutraceutical | |
| P42262 | GRIA2 | DB01664 | (S)-DES-ME-AMPA | experimental | |
| P42262 | GRIA2 | DB00898 | Ethanol | approved | |
| P42262 | GRIA2 | DB01483 | Barbital | illicit | antagonist |
| P42262 | GRIA2 | DB00237 | Butabarbital | approved, illicit | antagonist |
| P42262 | GRIA2 | DB07455 | N,N'-[biphenyl-4,4'-diyldi(2R)propane-2,1-diyl]dimethanesulfonamide | experimental | |
| P42262 | GRIA2 | DB00241 | Butalbital | approved, illicit | antagonist |
| P42262 | GRIA2 | DB08305 | (3R)-3-cyclopentyl-6-methyl-7-[(4-methylpiperazin-1-yl)sulfonyl]-3,4-dihydro-2H-1,2-benzothiazine 1,1-dioxide | experimental | |
| P42262 | GRIA2 | DB00463 | Metharbital | withdrawn | antagonist |
| P42262 | GRIA2 | DB02966 | Fluoro-Willardiine | experimental | |
| P42262 | GRIA2 | DB01351 | Amobarbital | approved, illicit | antagonist |
| P42262 | GRIA2 | DB03240 | (S)-2-Amino-3-(1,3,5,7-Pentahydro-2,4-Dioxo-Cyclopenta[E]Pyrimidin-1-Yl) Proionic Acid | experimental | |
| P42262 | GRIA2 | DB03319 | (2S)-2-Ammonio-3-[5-(2-methyl-2-propanyl)-3-oxido-1,2-oxazol-4-yl]propanoate | experimental | |
| P42262 | GRIA2 | DB02818 | Iodo-Willardiine | experimental | |
| P42262 | GRIA2 | DB07598 | 2,3,6A,7,8,9-HEXAHYDRO-11H-[1,4]DIOXINO[2,3-G]PYRROLO[2,1-B][1,3]BENZOXAZIN-11-ONE | experimental | |
| P42262 | GRIA2 | DB00794 | Primidone | approved, vet_approved | antagonist |
| P42262 | GRIA2 | DB01355 | Hexobarbital | experimental | antagonist |
| P42262 | GRIA2 | DB03759 | FG-9041 | experimental | |
| P42262 | GRIA2 | DB01174 | Phenobarbital | approved, investigational | antagonist |
| P42262 | GRIA2 | DB01354 | Heptabarbital | experimental | antagonist |
| P42262 | GRIA2 | DB00599 | Thiopental | approved, vet_approved | antagonist |
| P42262 | GRIA2 | DB01496 | Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione | experimental, illicit | antagonist |
| P42262 | GRIA2 | DB04000 | Bromo-Willardiine | experimental | |
| P42262 | GRIA2 | DB01352 | Aprobarbital | experimental, illicit | antagonist |
| P42262 | GRIA2 | DB01353 | Butobarbital | approved, illicit | antagonist |
| P42262 | GRIA2 | DB04152 | 2-Amino-3-(3-Hydroxy-7,8-Dihydro-6h-Cyclohepta[D]-4-Isoxazolyl)Propionic Acid | experimental | |
| P42262 | GRIA2 | DB04129 | Willardiine | experimental |
Related Diseases to GRIA2 |
| Previous studies relating to the alternative splicing of GRIA2 and disease information from the MeSH term (PubMed) |
| Gene | PMID | Title | Abstract | MeSH ID | MeSH term |
| GRIA2 | 15006707 | RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. | Editing and alternative splicing of mRNA are posttranscriptional steps probably involved in pathophysiological aspects of epilepsy. The present study analyses the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor subunit GluR2 with respect to the expression of (i) editing at the R/G site and (ii) flip-flop cassettes. Nervous tissue from patients with temporal lobe epilepsy was analysed by RT-PCR followed by restriction enzyme assays. Human autoptic tissue served as control. R/G editing status: the relative amount of edited RNA was significantly increased in the hippocampal tissue, whereas no changes were found in neocortical tissues. Flip-flop expression: no significant alterations were found in relative abundance of spliced variants containing the flip exon. The increased editing at the R/G site in the hippocampal tissue of epilepsy patients may enhance responses to glutamate, resulting in a synapse operating at an increased gain. | D004833 | Epilepsy, Temporal Lobe |
Clinically important variants in GRIA2 |
| (ClinVar, 04/20/2024) |
| accession_id | uniprot_id | gene_name | Type | Variant | Clinical_significance |
Copyright 2024-PresentThe University of Texas Health Science Center at Houston (UTHealth Houston) Web File Viewing | Emergency Information |